8-K: Exelixis Reports Strong Q2 Product Revenue Growth and Positive Clinical Milestones for Zanzalintinib

Exelixis announced its second quarter 2025 financial results, reporting $568.3 million in total revenues and $0.65 GAAP diluted EPS, while highlighting positive clinical trial outcomes for zanzalintinib and progress in its early-stage pipeline.

Summary

• Total revenues for Q2 2025 were $568.3 million, a decrease from $637.2 million in Q2 2024, primarily due to a non-recurring $150.0 million collaboration milestone recognized in Q2 2024.
• Net product revenues for Q2 2025 increased to $520.0 million from $437.6 million in Q2 2024, driven by increased sales volume.
• GAAP diluted EPS was $0.65 for Q2 2025, down from $0.77 in Q2 2024, though favorably impacted by lower weighted-average common shares outstanding due to stock repurchases.
• Non-GAAP diluted EPS was $0.75 for Q2 2025, down from $0.84 in Q2 2024.
• Research and development expenses decreased to $200.4 million in Q2 2025 from $211.1 million in Q2 2024.
• Selling, general and administrative expenses increased to $134.9 million in Q2 2025 from $132.0 million in Q2 2024.
• Exelixis is maintaining its full-year 2025 financial guidance, including total revenues of $2.25 billion $2.35 billion and net product revenues of $2.05 billion $2.15 billion.
• CABOMETYX received European Commission approval in July 2025 for previously treated advanced neuroendocrine tumors (NET), following U.S. FDA approval in March 2025.
• The U.S. CABOMETYX NET launch is showing early success, capturing a leading share of new patient starts among oral therapies in second-line and later settings, representing approximately four percent of overall CABOMETYX business in Q2 2025.
• Positive topline results from the Phase 3 STELLAR-303 pivotal study of zanzalintinib in combination with atezolizumab for metastatic colorectal cancer (CRC) demonstrated a statistically significant improvement in overall survival.
• Enrollment for the STELLAR-304 pivotal study in non-clear cell renal cell carcinoma was completed in May 2025, with top-line results expected in the first half of 2026.
• Exelixis decided not to proceed to the Phase 3 portion of the STELLAR-305 trial in advanced squamous cell carcinoma of the head and neck due to emerging data, competition, and other commercial opportunities.
• The STELLAR-311 Phase 3 pivotal trial in advanced NET was initiated during the quarter.
• Early-stage pipeline programs XL309, XB010, XB628 have ongoing Phase 1 clinical studies, and XB371 is moving into clinical investigation, while the XL495 program was discontinued.
• The 'One Big Beautiful Bill Act' signed on July 4, 2025, is estimated to provide a federal cash tax benefit of $147 million for previously unamortized domestic R&E expenditures.
• Positive developments in the cabozantinib patent estate include USPTO declining Azurity Pharmaceuticals' IPR petitions and a settlement agreement with Biocon Pharma Limited, granting a license to market a generic CABOMETYX in the U.S. starting January 1, 2031.
• Exelixis has repurchased $796.3 million of common stock at an average price of $36.69 per share under its stock repurchase programs, reducing weighted-average diluted common shares outstanding from 326.3 million to 284.4 million as of June 30, 2025.

Sentiment

Score: 8

Explanation: The filing demonstrates robust operational execution and significant progress across Exelixis's commercial and development pipeline. Despite a headline revenue decline, this was due to a non-recurring milestone from the prior year, while core product sales (CABOMETYX) showed strong growth and successful new market penetration. The positive Phase 3 STELLAR-303 results for zanzalintinib in a major indication like colorectal cancer represent a substantial value driver and potential future revenue stream. Furthermore, the successful defense of key patents and the strategic management of the pipeline, including the discontinuation of less promising programs to focus on larger opportunities, underscore sound management. The ongoing share repurchase program also signals management's confidence and commitment to shareholder value. These factors collectively point to strong underlying business health and significant growth potential.

Positives

• Net product revenues increased to $520.0 million in Q2 2025 from $437.6 million in Q2 2024, driven by sales volume.
• CABOMETYX received European Commission approval for advanced neuroendocrine tumors (NET) in July 2025, expanding its market.
• The U.S. CABOMETYX NET launch is showing strong early reception, capturing a leading share of new patient starts among oral therapies in second-line and later settings, contributing approximately four percent of overall CABOMETYX business in Q2 2025.
• Positive topline results from the Phase 3 STELLAR-303 trial for zanzalintinib in metastatic colorectal cancer (CRC) demonstrated a statistically significant improvement in overall survival.
• Enrollment completed for the STELLAR-304 pivotal study in non-clear cell renal cell carcinoma in May 2025.
• Initiation of the STELLAR-311 Phase 3 pivotal trial in advanced NET, expanding zanzalintinib's development.
• Advancement of early-stage pipeline programs (XL309, XB010, XB628, XB371) into Phase 1 clinical studies.
• Estimated federal cash tax benefit of $147 million due to the 'One Big Beautiful Bill Act' repealing R&E capitalization.
• Successful defense of cabozantinib patent estate with USPTO declining Azurity Pharmaceuticals' IPR petitions.
• Settlement agreement with Biocon Pharma Limited secures patent protection for CABOMETYX until January 1, 2031, in the U.S.
• Ongoing stock repurchase program has reduced weighted-average diluted common shares outstanding from 326.3 million to 284.4 million, favorably impacting EPS.

Negatives

• Total revenues decreased to $568.3 million in Q2 2025 from $637.2 million in Q2 2024, primarily due to a $150.0 million commercial milestone recognized in Q2 2024 that did not recur.
• GAAP diluted EPS decreased to $0.65 in Q2 2025 from $0.77 in Q2 2024.
• Non-GAAP diluted EPS decreased to $0.75 in Q2 2025 from $0.84 in Q2 2024.
• Decision not to proceed to Phase 3 for STELLAR-305 trial in advanced squamous cell carcinoma of the head and neck, indicating a strategic shift away from this indication.
• Discontinuation of the XL495 pipeline program based on early clinical data.

Risks

• The degree of market acceptance of CABOMETYX and other Exelixis products in approved indications and territories, and the ability to obtain or maintain coverage and reimbursement.
• The effectiveness of CABOMETYX and other Exelixis products compared to competing products.
• Costs associated with commercialization, research and development, in-licensing or acquisition of product candidates.
• Ability to maintain and scale adequate sales, marketing, market access, and product distribution capabilities or to maintain agreements with third parties.
• Potential failure of cabozantinib, zanzalintinib, and other product candidates to demonstrate safety and/or efficacy in clinical testing, alone or in combination.
• Uncertainties inherent in the drug discovery and product development process.
• Dependence on relationships with collaboration partners, including their pursuit of regulatory approvals, adherence to agreements, and investment in resources.
• Complexities and unpredictability of regulatory review and approval processes.
• Continuing compliance with applicable legal and regulatory requirements.
• Unexpected concerns from adverse safety events or additional data analyses of clinical trials.
• Dependence on third-party vendors for development, manufacture, and supply of products and candidates.
• Ability to protect intellectual property rights.
• Market competition, including the potential for generic versions of marketed products.
• Changes in economic and business conditions, including trade policies and tariffs.

Future Outlook

Exelixis plans to discuss the positive STELLAR-303 results with regulators for potential approval in metastatic colorectal cancer as soon as possible. Top-line results for the STELLAR-304 study in non-clear cell renal cell carcinoma are anticipated in the first half of 2026, contingent on study event rates. The company also intends to announce additional zanzalintinib pivotal trials in the coming months and will continue to track the CABOMETYX NET launch trajectory, providing updates to 2025 full-year financial guidance as appropriate. Early-stage pipeline program XB371 is expected to initiate Phase 1 study in the coming months.

Management Comments

• Exelixis continued to execute on our corporate objectives in the second quarter of 2025, delivering on key commercial, development and pipeline milestones.
• While early in the launch, we're very pleased with the reception that CABOMETYX has received in advanced neuroendocrine tumors (NET).
• Our commercial team rapidly mobilized on the U.S. NET launch following approval in March, capturing a leading share of new patient starts among oral therapies in second-line and later settings with NET representing approximately four percent of our overall CABOMETYX business in the second quarter.
• We will continue to track the launch trajectory and provide updates to our 2025 full year financial guidance, as appropriate.
• Turning to the zanzalintinib development program, in June, we announced positive topline results from the STELLAR-303 pivotal study in colorectal cancer. We plan to discuss these results with regulators with the intention of filing for approval in this indication as quickly as possible.
• Based on our evaluation of emerging data from the phase 2 portion of the STELLAR-305 study in advanced squamous cell carcinoma of the head and neck, emerging competition in this indication and assessment of other potentially larger commercial opportunities, we have made the decision not to proceed to the phase 3 portion of the trial.
• As we look ahead to the second half of the year, I'd like to thank the entire Exelixis team for their continued execution across our business, and for their dedication to our mission to help cancer patients recover stronger and live longer.

Industry Context

Exelixis operates in the highly competitive oncology market, where innovation in targeted therapies and immunotherapies is crucial. The positive STELLAR-303 results for zanzalintinib in colorectal cancer position it as a potential new treatment option in a significant indication, while the strategic decision to halt STELLAR-305 Phase 3 reflects the dynamic competitive landscape in head and neck cancer. The continued expansion of CABOMETYX into new indications like neuroendocrine tumors demonstrates the company's strategy to maximize its flagship product's lifecycle and market penetration. The advancement of multiple early-stage pipeline assets, including ADCs and bispecific antibodies, aligns with broader industry trends towards diversified therapeutic modalities beyond small molecules.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results to benchmark against industry standards.
• The decision not to proceed with STELLAR-305 Phase 3 was partly influenced by 'emerging competition in this indication,' implying that other therapies or development programs are advancing in the squamous cell carcinoma of the head and neck space.
• The company's focus on 'other potentially larger commercial opportunities' for zanzalintinib suggests a strategic prioritization in a competitive oncology development landscape.

Legal Proceedings

• The United States Patent and Trademark Office (USPTO) declined to institute Azurity Pharmaceuticals' petitions for inter partes review (IPRs) of U.S. Patent Nos. 11,298,349 and 12,128,039 in June and July 2025, respectively.
• Exelixis entered into a settlement agreement with Biocon Pharma Limited in July 2025, resolving patent litigation related to Biocon's Abbreviated New Drug Application (ANDA) for a generic version of CABOMETYX. Under the agreement, Biocon will be granted a license to market its generic version in the U.S. beginning January 1, 2031, subject to FDA approval and other conditions.

Stakeholder Impact

• Shareholders: Positive impact due to strong clinical trial results (STELLAR-303), new market approvals for CABOMETYX, active pipeline development, successful patent defense, and ongoing stock repurchase programs which reduce share count and enhance EPS.
• Patients: Potential for new treatment options with zanzalintinib in colorectal cancer and expanded access to CABOMETYX for neuroendocrine tumors.
• Employees: Continued execution across the business and advancement of pipeline programs suggest stability and ongoing opportunities.
• Competitors: The positive STELLAR-303 results and new approvals for CABOMETYX could intensify competition in relevant oncology indications. The strategic decision to exit STELLAR-305 Phase 3 indicates a response to emerging competition.
• Regulatory Authorities: Ongoing engagement with FDA and European Commission for drug approvals and IND clearances.

Next Steps

• Discuss STELLAR-303 results with regulators for potential filing for approval in metastatic colorectal cancer as quickly as possible.
• Present detailed STELLAR-303 results at a future medical meeting.
• Track the launch trajectory of CABOMETYX in advanced NET and provide updates to 2025 full-year financial guidance as appropriate.
• Announce an additional wave of zanzalintinib pivotal trials in the coming months.
• Initiate the Phase 1 study for XB371 in the coming months.
• Continue stock repurchases under the authorized programs until December 31, 2025.

Key Dates

Recommendation

The filing demonstrates robust operational execution and significant progress across Exelixis's commercial and development pipeline. Despite a headline revenue decline, this was due to a non-recurring milestone from the prior year, while core product sales (CABOMETYX) showed strong growth and successful new market penetration. The positive Phase 3 STELLAR-303 results for zanzalintinib in a major indication like colorectal cancer represent a substantial value driver and potential future revenue stream. Furthermore, the successful defense of key patents and the strategic management of the pipeline, including the discontinuation of less promising programs to focus on larger opportunities, underscore sound management. The ongoing share repurchase program also signals management's confidence and commitment to shareholder value. These factors collectively point to strong underlying business health and significant growth potential.

Keywords

Exelixis, EXEL, Oncology, Cancer, CABOMETYX, Cabozantinib, Zanzalintinib, Neuroendocrine Tumors, Colorectal Cancer, Renal Cell Carcinoma, Drug Development, Clinical Trials, SEC Filing, Financial Results, Biotechnology, Pharmaceuticals, Patent Litigation, Stock Repurchase